Search

Displaying results 11 - 20 of 21 in total
  1. Drug

    Omfiloctocog alfa

    go.drugbank.com/drugs/DB19229
    Investigational

    Omfiloctocog alfa is under investigation in clinical trial NCT03947567 (Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia a Patients.).

    Synonyms: FACTOR VIII (RECOMBINANT HUMAN SCT800 LIGHT, HUMAN COAGULATION FACTOR VIII (FVIII, ANTIHEMOPHILIC FACTOR, AHF, PROCOAGULANT COMPONENT) WITH DELETED B-DOMAIN (746-1639)-SEQUENCE: SINGLE-CHAIN RECOMBINANT FVIII COMPOSED OF DOMAINS A1-A1-A2-A2 (1-740
  2. Pathway

    Antihemophilic Factor Human Recombinant Action Pathway

    smpdb.ca/view/SMP0126774
    Drug action

    Antihemophilic factor, human recombinant is administered intravenously and acts to correct coagulation defects, by activating coagulation factor X and IX. … Antihemophilic factor, human recombinant of the coagulation Factor VIII, also known as Advate, Adynovate, Helixate, Kogenate, Kovaltry, Novoeight, Recombinate, to treat hemophilia A, von Willebrand disease

    Drugs: Antihemophilic factor, human recombinant · Calcium
    Enzymes: Tissue factor, Coagulation factor VIII
  3. Pathway

    Antihemophilic Factor Human Action Pathway

    smpdb.ca/view/SMP0126841
    Drug action

    Antihemophilic factor human, also known as Hemofil, Koate, and Wilate is used as factor VIII replacement therapy to treat hemophilia A. … Administered intravenously the antihemophilic factor human replaces the abnormal coagulation factor VIII, acting as a cofactor to activate coagulation factor IX and X.

    Drugs: Calcium · Antihemophilic factor human
    Enzymes: Tissue factor, Coagulation factor VIII
  4. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    Simoctocog alfa is a recombinant B-domain deleted (BDD) rFVIII produced in genetically modified human embryonic kidney (HEK) 293F cells. … Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life [A31525]

  5. Drug

    Damoctocog alfa pegol

    go.drugbank.com/drugs/DB14700
    ApprovedInvestigational

    In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. … [A38907] Also known as, BAY94-9027, Damoctocog alfa pegol is a longer-acting Factor VIII therapy formulated with polyethylene glycol (PEG) to reduce the number of infusions necessary to prevent bleeds

    Categories: Blood Coagulation Factors
  6. Indication

    Joint Damage

    go.drugbank.com/conditions/DBCOND0046483
    Drugs: Antihemophilic factor, human recombinant
  7. Indication

    Perioperative Blood Loss

    go.drugbank.com/conditions/DBCOND0049110
    Drugs: Albutrepenonacog alfa · Antihemophilic factor (recombinant), PEGylated · Antihemophilic factor, human recombinant · Efanesoctocog alfa · Efmoroctocog alfa · Factor XIII (human) +1 more
  8. Indication

    Hemorrhage

    go.drugbank.com/conditions/DBCOND0022978
    Drugs: Aluminum sulfate · Aminocaproic acid · Antihemophilic factor (recombinant), PEGylated · Antihemophilic factor human · Antihemophilic factor, human recombinant · Beroctocog alfa +21 more
  9. Pathway

    Moroctocog Alfa Action Pathway

    smpdb.ca/view/SMP0126849
    Drug action

    Moroctocog alfa also known as Refacto AF and Xyntha, is a B-domain deleted recombinant factor VIII similar to the endogenous coagulation factor VIII. … It acts by replacing coagulation factor VIII which is deficient in those with hemophilia, this allows coagulation factor IX and X to be activated and facilitate the clotting cascade.

    Drugs: Calcium · Moroctocog alfa
    Enzymes: Tissue factor, Coagulation factor VIII
  10. Indication

    Bleeding caused by Hemophilia B

    go.drugbank.com/conditions/DBCOND0089514
    Drugs: Anti-inhibitor coagulant complex · Coagulation Factor IX Human · Coagulation factor VIIa Recombinant Human · Eftrenonacog alfa · Fitusiran · Nonacog beta pegol